Innovation
Tue, Mar 26, 2024 2:57 PM

Egis' medicines won the Innovation Grand Prize

Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize.
Innovation

Egis' medicines won the Innovation Grand Prize

Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize.
Tue, Mar 26, 2024 2:57 PM
Author:
Tue, Mar 26, 2024 2:57 PM
Author:

The awarded Egis medicines can replace the concurrent administration of ezetimibe and rosuvastatin, or ezetimibe and atorvastatin, often taken simultaneously in the therapy of cardiovascular diseases. 
The innovative fixed-dose combination drugs contain both active ingredients, allowing the patient to take just one medication instead of two.
Developing these drugs posed several special challenges for the professionals at Egis. The active substances in question behave differently in many respects, and enclosed in the same capsule they can react with each other, potentially affecting each other's dissolution and bioavailability.
By processing the active ingredients in separate platform elements and by significantly reducing the contact surface, the interaction between them was finally minimized.
"We are especially proud that the active ingredient rosuvastatin is the result of Egis' own generic development and is currently manufactured by our company - said Csaba Poroszlai at the award ceremony. - During its development, our researchers successfully identified the zinc salt of rosuvastatin which is beneficial from stability point of view, and its crystalline form, which has proven to be highly suitable to be developed as an active pharmaceutical ingredient."
Additionally, a non-infringing, robust, high-yielding, and scalable drug manufacturing process has been elaborated at Egis. It is based on an unconventional chemical step.
An effective solution to one of the cornerstones of formulation development has also been found, namely, to increase the solubility and bioavailability of the active ingredient ezetimibe. Eliminating the disadvantages of known methods, it provides the required particle size distribution to achieve the desired dissolution rate.
Csaba Poroszlai, CEO of Egis Pharmaceuticals PLC received the award from Dr. Csaba Hende, Deputy Speaker of the National Assembly and Dr. Eszter Vitályos, Deputy Minister of the Ministry of Culture and Innovation  in the House of Parliament on March 26, 2024.

#products #prize #award
Related articles from Egis Magazine
Egis World

Professional award for our joint project with the Örkény Theatre
More
Egis World

Another grand prize for our company's career guidance program
More
Egis World

Dr István Hodász, former CEO of Egis received the Golden Medal award of the Hungarian Chamber of Pharmacists
More

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox